Sugi Predict

Sugi Predict / Compounds / SCHEMBL15067601

SCHEMBL15067601

SCHEMBL15067601

COc1ncc(Br)c(C=CN(C)C)c1[N+](=O)[O-]

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ CA1 P00915 2/20 0.38
▸ CA2 P00918 2/20 0.38
▸ CA7 P43166 2/20 0.38
▸ CA13 Q8N1Q1 2/20 0.38
▸ MMP14 P50281 2/20 0.33
▸ POLB P06746 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ KMT2A Q03164 2/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ GRIN2D O15399 1/20 0.31
▸ GRIN3B O60391 1/20 0.31
▸ GRIN1 Q05586 1/20 0.31
▸ GRIN2A Q12879 1/20 0.31
▸ GRIN2B Q13224 1/20 0.31
▸ GRIN2C Q14957 1/20 0.31
▸ GRIN3A Q8TCU5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31395611 1.00 MAPT (0.49) MAPTALDH1A1CA1CA2CA7
SCHEMBL12033232 1.00 MAPT (0.49) MAPTALDH1A1CA1CA2CA7
SCHEMBL30073354 1.00 MAPT (0.49) MAPTALDH1A1CA1CA2CA7
SCHEMBL15067956 0.94 MAPT (0.44) MAPTALDH1A1CA1CA2CA7
SCHEMBL15067955 0.94 MAPT (0.44) MAPTALDH1A1CA1CA2CA7
SCHEMBL24365089 0.88 ALDH1A1 (0.38) MAPTALDH1A1CA1CA2CA7
SCHEMBL12528073 0.85 MAPT (0.50) MAPTALDH1A1CA1CA2CA7
SCHEMBL13593456 0.85 MAPT (0.50) MAPTALDH1A1CA1CA2CA7
SCHEMBL16045089 0.84 MAPT (0.49) MAPTALDH1A1CA1CA2CA7
SCHEMBL14605727 0.84 MAPT (0.49) MAPTALDH1A1CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12636290-B2 BET inhibitors for modulating DUX4 expression in FSHD SAINT LOUIS UNIVERSITY (US) 2026-05-26 — — US disclosed
EP-4342543-B1 TERT-BUTYL 2-(4-PHENYL-6H-THIENO[3,2-F][1,2,4]TRIAZOLO[4,3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER HOFFMANN LA ROCHE (CH) 2026-04-29 — — EP disclosed
US-20260092065-A1 CRYSTALLINE SOLID FORMS OF A BET INHIBITOR INCYTE CORP (US) 2026-04-02 — — US disclosed
US-12459943-B2 Crystalline solid forms of a BET inhibitor INCYTE CORPORATION (US) 2025-11-04 — — US disclosed
US-20250084096-A1 TERT-BUTYL (S)-2-(4-(PHENYL)-6H-THIENO[3, 2-F][1, 2, 4]TRIAZOLO[4, 3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AND RELATED COMPOUNDS AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER GENENTECH, INC. (US) 2025-03-13 — — US disclosed
US-12152040-B2 Tert-butyl (s)-2-(4-(phenyl)-6H-thieno[3, 2-f][1, 2, 4]triazolo[4, 3-a] [1,4]diazepin-6-yl) acetate derivatives and related compounds as bromodomain BRD4 inhibitors for treating cancer GENENTECH, INC. (US) 2024-11-26 — — US disclosed
US-20240360124-A1 Bromodomain Inhibitors ABBVIE INC. (US) 2024-10-31 — — US disclosed
US-20240309001-A1 CRYSTALLINE SOLID FORMS OF A BET INHIBITOR INCYTE CORPORATION 2024-09-19 — — US disclosed
US-12030882-B2 Crystalline solid forms of a bet inhibitor INCYTE CORPORATION (US) 2024-07-09 — — US disclosed
EP-3849987-B1 TERT-BUTYL (S)-2-(4-(PHENYL)-6H-THIENO[3,2-F][1,2,4]TRIAZOLO[4,3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AND RELATED COMPOUNDS AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER HOFFMANN LA ROCHE (CH) 2024-04-17 — — EP disclosed
EP-3013826-A1 CRYSTALLINE BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2016-05-04 — — EP disclosed
EP-3013828-A1 BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2016-05-04 — — EP disclosed
US-9321765-B2 Crystalline bromodomain inhibitors ABBVIE INC. (US) 2016-04-26 — — US disclosed
US-9296741-B2 Bromodomain inhibitors ABBVIE INC. (US) 2016-03-29 — — US disclosed
US-20160039821-A1 TETRACYCLIC BROMODOMAIN INHIBITORS ABBVIE INC. 2016-02-11 — — US disclosed
US-20150005340-A1 CRYSTALLINE BROMODOMAIN INHIBITORS ABBVIE INC. 2015-01-01 — — US disclosed
WO-2014206150-A1 BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2014-12-31 — — WO disclosed
WO-2014210425-A1 CRYSTALLINE BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2014-12-31 — — WO disclosed
US-20140162971-A1 BROMODOMAIN INHIBITORS ABBVIE INC. 2014-06-12 — — US disclosed
WO-2013097052-A1 BROMODOMAIN INHIBITORS ABBOTT LABORATORIES (US) 2013-07-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030882-B2 Crystalline solid forms of a bet inhibitor BRD1, BRD3, BRD2 MAPT 612/4885ALDH1A1 4804/4885CA1 3670/4885
US-20250084096-A1 TERT-BUTYL (S)-2-(4-(PHENYL)-6H-THIENO[3, 2-F][1, 2, 4]TRIAZOLO[4, 3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AND RELATED COMPOUNDS AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER BRD4, BRD3, BRD2 MAPT 1299/4885ALDH1A1 4236/4885CA1 4637/4885
US-12459943-B2 Crystalline solid forms of a BET inhibitor BRD1, BRD3, BRD2 MAPT 612/4885ALDH1A1 4804/4885CA1 3670/4885
US-20140162971-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 MAPT 2252/4885ALDH1A1 1794/4885CA1 1571/4885
US-20160039821-A1 TETRACYCLIC BROMODOMAIN INHIBITORS BRD3, BRD4, BRD1 MAPT 1294/4885ALDH1A1 2065/4885CA1 1950/4885
US-20260092065-A1 CRYSTALLINE SOLID FORMS OF A BET INHIBITOR BRD2, BRDT, BRD1 MAPT 264/4885ALDH1A1 4803/4885CA1 4052/4885
US-12152040-B2 Tert-butyl (s)-2-(4-(phenyl)-6H-thieno[3, 2-f][1, 2, 4]triazolo[4, 3-a] [1,4]diazepin-6-yl) acetate derivatives and related compounds as bromodomain BRD4 inhibitors for treating cancer BRD4, BRD3, BRD2 MAPT 1299/4885ALDH1A1 4236/4885CA1 4637/4885
US-12636290-B2 BET inhibitors for modulating DUX4 expression in FSHD BRDT, BET1, PHKB MAPT 4498/4885ALDH1A1 3913/4885CA1 4625/4885
US-20240309001-A1 CRYSTALLINE SOLID FORMS OF A BET INHIBITOR BRD1, BRD3, BRD2 MAPT 612/4885ALDH1A1 4804/4885CA1 3670/4885
US-20240360124-A1 Bromodomain Inhibitors BRD4, BRD3, BRD1 MAPT 2044/4885ALDH1A1 3060/4885CA1 3394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.